Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC